Create your personal agenda –check the favourite icon
Workshop A - Antibodies: Discovery vs Computational Design
Pre-congress workshops
Series of presentations followed by panel discussion
Computational design of antibodies-Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory
Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV-Dr Phillip Lovanti,Sr. Director of R&D, Aridis Pharmaceuticals
Machine learning models for design of antibodies -Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech
Computational and artificial intelligence-based methods for antibody development -Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto
How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School
M1
Workshop B - Infodemiology as a means to engage with health care and public health
Pre-congress workshops
Infodemiology as a means to engage with health care and public health
This session is part program launch, and part interactive workshop. The U.S. "House of Medicine" represents all national medical boards in the country. Led by the American Board of Internal Medicine (ABIM) and public health nonprofit PGP, the House of Medicine has launched the Health Care Infodemiology Brief. Infodemiology is the study of information's impact on health, particularly online information. Vaccine confidence is driving the adoption of infodemiology. This resource helps clinicians better understand trending health narratives and debunk false claims to which their patients may have been exposed. The Health Care Infodemiology Brief examines vaccines and other topics that are the subjects of most false claims found on social media and online.
This workshop will introduce participants to the Health Care Infodemiology Brief, its parent program integrating infodemiology throughout health care, and its sister programs integrating media monitoring, analyses, and reporting throughout public health. Mitigating the impact of vaccine misinformation and increasing vaccine confidence is a central focus of these programs.
Following this overview, workshop participants will be shown how infodemiology works in practice. Live dashboards of public conversations, examples of misinformation, and exercises to think through communications and reporting will be conducted. PGP experts are frequent speakers at WVC events and have deep knowledge of current pharmaceutical industry efforts to support health care and public health. They know what they're talking about and enjoy what they do. Stop on by!
M2
Create your personal agenda –check the favourite icon
Opening Keynote: Cracking the code of immunity: The latest breakthroughs in systems immunology for uncovering the secrets of human immunity to vaccines and infections
Keynotes
HALL B
Keynote presentation: Lessons from the pandemic: ensuring a bright future for vaccine development, administration, and confidence
Keynotes
HALL B
Fireside chat: Government perspective & priorities on the future of pandemic preparedness in the USA
Keynotes
- Priority areas for funding
- How does small biotech to big pharma work under the new loan authority?
- What does the future look like for government agencies
HALL B
Keynote Panel: Navigating the future of RSV Vaccines & Therapies: Tailoring Approaches from Maternal to Adults
Keynotes
- Now there are vaccines available, what is the right approach for adults vs infants & maternal?
- What is the optimal recommendation for use of different technologies based on the epidemiology of the disease?
- Practical issues, health economics & policy considerations
- Cost-effectiveness challenges
- Remaining needs in older adults; how to protect in the second season and beyondHow to combat vaccine fatigue with new combinations and other approaches
- The ecosystem of respiratory tract infections in the absence of RSV
Michael Greenberg, Head of North American Medical, Sanofi Vaccines
Cassia Cearley, Chief Business Officer, Icosavax, Inc.
HALL B
Exhibition & Partnering Break - Morning
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Roundtable 1. Ensuring clinical trial enrollment, retention, and diversity
Interactive Roundtables
M1
Roundtable 2. Incorporating post-viral diseases into your company’s clinical & market strategy
Interactive Roundtables
M2
Roundtable 3. Stand out from the crowd - How can biotechs grab investors’ attention?
Interactive Roundtables
M3
Roundtable 4. The policy & politics of vaccine mandates in California and around the world
Interactive Roundtables
B4
Roundtable 5. Partnerships to advance diverse leadership pipelines in biotechnology companies
Interactive Roundtables
B5
Exhibition & Partnering Break - Lunch
Keynotes
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Start-up: A simple, safe, affordable, and scalable intradermal delivery platform for nucleic acid vaccines and therapeutics
Start-up Pitches
Gaurav Byagathvalli, Chief Executive Officer and co-founder, Piezo Therapeutics, Inc.
HALL B
Start-up: Where innovation meets sustainability: Discover the Q-VANT breakthrough
Start-up Pitches
HALL B
Start-up: Next Generation AI and saRNA and saDNA Platforms on Demand
Start-up Pitches
HALL B
Start-up: MACH-1TM Epidermally Delivered Powdered Vaccine Platform
Start-up Pitches
HALL B
Chair's Opening Remarks
Infectious Disease Vaccines
B4
Chair's Opening Remarks
Cancer Immunotherapy
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
B5
Chair's Opening Remarks
Immune Profiling
Philip Felgner, Director, Vaccine R&D Center, University of California at Irvine
M2
Chair's Opening Remarks
Clinical Trials
M1
Chair's Opening Remarks
COVID-19 & Beyond
HALL B
Chair's Opening Remarks
Antiviral Therapies
M3
A Phase 3 Study to Evaluate the safety, tolerability, and immunogenicity of V116, a pneumococcal conjugate vaccine designed for adults (STRIDE-3)
Infectious Disease Vaccines
B4
Allogeneic EBV T-Cell Therapies: Ushering in the Next Wave of Innovation
Cancer Immunotherapy
B5
High throughput analysis of B cell dynamics and neutralizing antibody development during HIV immunization
Immune Profiling
M2
A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases
Clinical Trials
M1
Development of a DNA-encoded monoclonal antibody for COVID-19
COVID-19 & Beyond
Diana Guimet, Principal Scientist, Inovio Pharmaceuticals
HALL B
Development of Cloudbreak Drug-FC conjugates for the prevention of seasonal influenza
Antiviral Therapies
M3
Understanding the immunogenicity of a 21-valent pneumococcal conjugate vaccine
Infectious Disease Vaccines
B4
Development of 24-valent & next generation 31-valent PCV Vaccines
Infectious Disease Vaccines
B4
Targeting HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers
Cancer Immunotherapy
B5
Small protein mimetics of HIV-1 broadly neutralizing antibody epitopes represent promising tool for induction of HIV-1-neutralizing antibodies
Immune Profiling
M2
Reducing protocol deviations and increasing data quality in vaccine trials
Clinical Trials
Eric Elander, Director of Business Development, Clinical Research IO (CRIO)
M1
Engineered antibodies in the face of viral evolution
COVID-19 & Beyond
HALL B
Encrypted RNA: A new class of RNA for inhalable & variant-proof immunity
Antiviral Therapies
M3
From the Lab to the Jab and Back Again: AstraZeneca’s COVID-19 Monoclonal Antibody Response
COVID-19 & Beyond
HALL B
Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Pediatric Population
Infectious Disease Vaccines
Sylvie PICHON, Global Clinical Development Strategy Expert, Sanofi
B4
Clinical trials in HPV+ head and neck cancers
Cancer Immunotherapy
B5
The pertussis puzzle: exploring the effectiveness of novel vaccination targets
Immune Profiling
M2
Building a pipeline of black and diverse physician clinical research trial PIs
Clinical Trials
M1
Boosting your defenses: The impact of additional covid-19 vaccine doses on t-cell responses
COVID-19 & Beyond
HALL B
Predicting / profiling genetic barriers to resistance of antibody-based inhibitors
Antiviral Therapies
M3
Targeting Staphylococcus aureus virulence for vaccination and immunotherapy
Infectious Disease Vaccines
B4
Identification of immune modulating microbial proteins in cancer
Cancer Immunotherapy
B5
Consultative design for influenza vaccine development – reverse genetics approaches for assay development and sample testing
Immune Profiling
M2
Improving clinical trial recruitment
Clinical Trials
M1
AI empowered infectious disease vaccine development
COVID-19 & Beyond
HALL B
Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344
Antiviral Therapies
M3
Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays
Immune Profiling
M2
Exhibition & Partnering Break - Afternoon
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Safety & immunogenicity of MVX01 Pneumococcal Vaccine
Infectious Disease Vaccines
B4
Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity
Cancer Immunotherapy
B5
Characterization of broadly neutralizing mAbs against SARS-CoV-2 and influenza using a lentivirus pseudotype platform
Immune Profiling
M2
Partnering for success within vaccine clinical trials
Clinical Trials
Tina Morgenstein, Project Director in the Vaccine Therapeutic Unit, PPD, Part of Thermo Fisher Scientific
M1
COVID-19 Vaccines for immunocompromised patients
COVID-19 & Beyond
HALL B
Remdesivir – a broad-spectrum antiviral and COVID-19 therapeutic
Antiviral Therapies
M3
Panel: Beyond PCV13: Exploring the Future of Pneumococcal Disease Vaccines
Infectious Disease Vaccines
- The current state of pneumococcal disease vaccine development and the limitations of PCV13.
- New approaches to vaccine development, such as protein-based vaccines, conjugate vaccines, and combination vaccines
- The potential impact of new vaccines on disease prevention and public health
- Case for maternal immunization?
- Challenges and opportunities for vaccine development in low- and middle-income countries
B4
Novel Vaccinia Enhanced Template (VET) oncolytic platform
Cancer Immunotherapy
B5
Multiplexed immune profiling for sars-cov-2 prevalence, asymptomatic infections and vaccine coverage
Immune Profiling
M2
BPZE1 Induces Serum Bactericidal Activity against Pertactin-Positive and Pertactin-Deficient B. Pertussis
Clinical Trials
M1
Panel: Beyond Vaccines: Exploring the power and potential of prophylactic antibodies
COVID-19 & Beyond
HALL B
Panel: Bridging the divide - animal rule to clinical development
Antiviral Therapies
- Use of pre-clinical models to inform licensure
- Regulatory pathways
- International coordination on clinical trials
Shazia Ali, Senior Director, Regulatory Affairs, Regeneron Pharmaceuticals
Danielle Craig, Regulatory Affairs Lead Americas, CEPI
M3
MULTI-seq: lipid-conjugated DNA barcodes for multiplexed single-cell sequencing
Immune Profiling
M2
INO-3107 program for the treatment of Recurrent Respiratory Papillomatosis
Clinical Trials
M1
Create your personal agenda –check the favourite icon
Opening Keynote: Could antibodies be the principal tool with which we manage future viral pandemics?
Keynotes
HALL B
ASPR’s Office of Industrial Base Management and Supply Chain (IBMSC) - Domestic manufacturing for therapeutics and other critical medical products
Keynotes
HALL B
Keynote Panel: Moving to the left: The maturing applications of ct & cf DNA in oncology
Keynotes
- What progress has been made? Recent approvals.
- As yet untapped potential uses of ctDNA in oncology
- Success in prediction but difficulty of use in later stage development
- Do certain phenotypes amongst circulating immune cells dictate responsiveness to certain IO drugs or combinations?
Moderator: Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
Mohan Bolisetty, Associate Director, Bristol-Myers Squibb
HALL B
Keynote Panel: SupeRNAtural: Realizing the potential of RNA therapeutics for ID & Cancer
Keynotes
There are a wide variety of RNA molecules used to inhibit infectious diseases and cancer, a discussion of the common challenges in:
- Targeting multiple antigens simultaneously
- Safety - More RNA = more side effects
- Achieving equal expression
- Delivering effective doses with lower amounts
- Combination vaccines
- Formulation
- T-cells
HALL B
Exhibition & Partnering Break - Morning
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Chair's Opening Remarks
Infectious Disease Vaccines
B4
Chair's Opening Remarks
Cancer Immunotherapy
Michael Salgaller, Supervisor, Invention Development And Marketing Unit, National Cancer Institute - NIH
B5
Chair's Opening Remarks
Immune Profiling
M2
Chair's Opening Remarks
COVID-19 & Beyond
HALL B
Chair's Opening Remarks
Antiviral Therapies
M3
Chair's Opening Remarks
Bioprocessing, Manufacture & Delivery
M1
Late-stage maternal RSV vaccine development
Infectious Disease Vaccines
B4
Priming cold tumors through GVAX and early development of mutated KRAS peptide & mRNA vaccines targeting multiple NeoAgs
Cancer Immunotherapy
B5
Single cell analysis - Is it ready for the clinic?
Immune Profiling
Mohan Bolisetty, Associate Director, Bristol-Myers Squibb
M2
PROTAC approach for antiviral drug discovery of coronaviruses
COVID-19 & Beyond
HALL B
Hepatitis therapeutics and vaccines development
Antiviral Therapies
M3
Supporting the development of vaccine manufacture in LMICs
Bioprocessing, Manufacture & Delivery
Robert Sitrin, Senior Scientist, PATH
M1
Clinical development of an intranasal live attenuated RSV vaccine for infants
Infectious Disease Vaccines
B4
Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)
Cancer Immunotherapy
B5
A cfDNA assay to monitor early escape
Immune Profiling
M2
Ensitrelvir - an Oral 3CL Protease Inhibitor for the treatment of COVID-19
COVID-19 & Beyond
HALL B
mRNA-based Hepatitis Tx development
Antiviral Therapies
M3
Self-assembling nanoliposomal system, molecular adjuvants and mucoadhesive nanofibre based films for construction of recombinant vaccines
Bioprocessing, Manufacture & Delivery
M1
From computationally designed antigens to VLP-based antigen display – a recipe for best-in-class vaccines
Infectious Disease Vaccines
B4
Development p53MVA vaccine with pembrolizumab
Cancer Immunotherapy
B5
Immune profiling from blood in clinical trials
Immune Profiling
M2
An ACE2 decamer viral trap by IgM frame as a durable solution for SARS-CoVs
COVID-19 & Beyond
HALL B
Early development of novel anti-HBV ribonuclease H inhibitors
Antiviral Therapies
M3
Applications of the MYO technology platform for DNA-Based antibody delivery
Bioprocessing, Manufacture & Delivery
M1
Exhibition & Partnering Break - Lunch
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Computational bioengineering of broad-spectrum mRNA LNP vaccines
Infectious Disease Vaccines
B4
Merck/Moderna cancer vaccine combination study
Cancer Immunotherapy
B5
In situ tumor arrays reveal early environmental control of cancer immunity
Immune Profiling
M2
Broadly acting cathepsins inhibitors against COVID-19 and emerging infectious diseases
COVID-19 & Beyond
HALL B
Clinical updates for NAPs in HBV and HDV: multiyear follow-up from phase II studies and compassionate use in cirrhotic patients
Antiviral Therapies
M3
Redefining Access: Prefilled injectables for safe and efficient vaccinations
Bioprocessing, Manufacture & Delivery
M1
How Human challenge studies facilitate effective vaccine transmission blocking efficacy testing
Infectious Disease Vaccines
Senior Representative, hVIVO
Andrew Catchpole, CSO, hVIVO
B4
Demonstration of a universal preventative cancer vaccine
Cancer Immunotherapy
B5
Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
Immune Profiling
M2
Discovery & development of small molecule viral assembly modulators against respiratory pathogens
COVID-19 & Beyond
Vishwanath Lingappa, Chief Executive Officer, Chief Technology Officer And Member Board Directors, Prosetta Biosciences
HALL B
Addressing the Unmet Need for a Functional Cure for Chronic Hepatitis B
Antiviral Therapies
M3
Sustainable production of Quillaja saponins for vaccine adjuvants
Bioprocessing, Manufacture & Delivery
M1
Use of adjuvants to drive appropriate immune responses to respiratory disease vaccines; Pertussis, TB, COVID
Infectious Disease Vaccines
B4
AMPLIFY Vaccine Platform: repRNA + LION™
Cancer Immunotherapy
B5
JO – opening tumor junctions to treat cancer
Immune Profiling
M2
Development of small bispecifc drugs targeting influenza and other respiratory diseases
COVID-19 & Beyond
HALL B
Advancing CARG-201, a self-amplifying mRNA vaccine for immunotherapy of chronic hepatitis B, from animal models to clinical trials
Antiviral Therapies
M3
Securing a Resilient Future: Sustainable Supply of Saponins for Global Vaccine Development
Bioprocessing, Manufacture & Delivery
M1
Exhibition & Partnering Break - Afternoon
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
HALL A
BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study
Infectious Disease Vaccines
B4
Panel: Unleashing the Power of Cancer Vaccines: Strategies for the Future
Cancer Immunotherapy
B5
Furthering innovative ideas in oncology through NCIs PREVENT Network
Immune Profiling
M2
Development of an Oral, Broad-Spectrum Antiviral Therapeutic for Respiratory Viruses
COVID-19 & Beyond
HALL B
Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure
Antiviral Therapies
li>- How do you define a functional / partial cure – how should we use these terms and what are their limitations?
- Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA
- Components to an effective cure strategy:
o Use of viral replication inhibitors
o Reducing viral surface antigen load – do we still have room to further reduce load?
o Activation of antiviral immune response
- Challenges in balancing side-effects and therapeutic efficacy
How do we manage / avoid resistance
M3
Trends in dry product manufacturing for vaccines
Bioprocessing, Manufacture & Delivery
M1
Moving From the Lab to the Clinic: Clinical Implementation Challenges of CPG, MRD and Screening
Immune Profiling
M2
Create your personal agenda –check the favourite icon
Keynote Panel: Beyond Borders: Collaborating for success in developing vaccines for emerging infectious diseases
Keynotes
- Challenges around stock piling vaccines that are not yet licensed –
- need for (relatively small) stockpiles of “vialed and quality-tested vaccines that are ready to be clinically tested in populations as soon as the next outbreak strikes”.
- Is stockpiling the victim of market failure?
- Funding mechanisms decoupled from the market
- Aligning programmatic interests during outbreaks and “peace times
- Experiences getting Sudan Ebola vaccines to Uganda
- Alternative regulatory pathways and accelerated development
- Aligning interests & objectives of international funding partners
Danielle Craig, Regulatory Affairs Lead Americas, CEPI
HALL B
Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems
Keynotes
- Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
- Are broad-spectrum (pan-variant) prophylactics a possible way forward?
- When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
- Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
- Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
- Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?
HALL B
Exhibition & Partnering Break - Morning
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Chair's Opening Remarks
Infectious Disease Vaccines
Jessica Malaty Rivera, Research Assistant, Johns Hopkins Center For Health Security
B4
Chair's Opening Remarks
Antiviral Therapies
M3
Chair's Opening Remarks
New Technology
M1
Chair's Opening Remarks
Partnerships
M2
Vaccine development programs for emerging infectious diseases; lassa, marbug, Ebola Sudan
Infectious Disease Vaccines
B4
LOQTORZITM (toripalimab-tpzi) – a next generation PD-1 inhibitor
Cancer Immunotherapy
B5
Development of broad-spectrum protease inhibitors to combat emerging viral diseases
Antiviral Therapies
Byron Martina, Protinhi Therapeutics
M3
Sera from mice vaccinated with Epstein-Barr virus-like particles potently prevent infection of human B cells and epithelial cells in vitro
New Technology
M1
Panel: De-risking therapeutics drug development for infectious diseases –
Partnerships
- Road to repurposing and expanding use of broad-spectrum antivirals
- Setting up public private partnerships
- Alignment of interests
- Commercial risks of clinical trials
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
Diane Griffin, Vice President, National Academy of Sciences, Professor, Molecular Microbiology And Immunology, Johns Hopkins Bloomberg School of Public Health
M2
TB vaccine development: From clinical trials to market access - current status and future perspectives
Infectious Disease Vaccines
B4
Progress in the clinical development of bispecific t-cell engagers as monotherapies and in combination
Cancer Immunotherapy
B5
Identification of small molecule inhibitors against the nsP2 protease (nsP2pro) of Chikungunya virus
Antiviral Therapies
M3
Targeting HIV-1 and Beyond: Novel Protein Nanoparticles as Vaccine Platforms
New Technology
M1
Early development of next generation malaria VLP vaccines that target vulnerable epitopes
Infectious Disease Vaccines
Bryce Chackerian, Professor, University of New Mexico School of Medicine
B4
Development of cancer immunotherapies targeting the STING pathway
Cancer Immunotherapy
Glen Barber, Chief Executive Officer, STINGINN; Chairman and Professor, Department of Cell Biology, University of Miami
B5
Identification of broad-spectrum antivirals for emerging viral diseases
Antiviral Therapies
Vaithilingaraja Arumugaswami, Co-Founder, Veergen Inc. ; Professor, Department of Molecular and Medical Pharmacology, University of California, Los Angeles
M3
Development of saponin-based adjuvant IA-05 for subunit-vaccines
New Technology
Richard Guy, Global Business Development, ImmunAdd Inc.
M1
Fireside chat: Engaging with public-private partnerships to accelerate multi-use technologies with commercial and preparedness applications
Partnerships
Innovation is a journey that can be complex and unpredictable, but it does not have to follow a singular path. Leveraging opportunities to collaborate with multiple stakeholders, including through public-private partnerships, can accelerate innovation and yield unique advantages.
During this session, Dr.Michael Egan, CEO of CastleVax, will share insights on how the CastleVax technology has been accelerated by leveraging opportunities such as New York State funding, incubation through BLUE KNIGHT™ at JLABS @ NYC, partnering with another BLUE KNIGHT™ company to be awarded $1M through the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen, and a Project NextGen award to support a phase 2b clinical trial.
In a conversation with Dan Wolfe, Branch Chief, CBRN Vaccines at BARDA, the discussion will highlight leveraging complementary opportunities to accelerate next generation potential solutions and how BARDA engages in public-private partnerships to support early-stage companies.
Michael Egan, CEO/CSO, CastleVax
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
M2
Exhibition & Partnering Break
Keynotes
Tea, Coffee and Refreshments served in the exhibition area
One-to-one networking meetings, Poster Presentations
So you can plan ahead there will be a Café station open in the exhibition from 8am-5pm where you can purchase tea, coffee and pastries until 11am, and then purchase hot food till 3pm.There will also be another open from 11am-3pm where you can purchase salads, sandwiches, drinks and other snacks
HALL A
Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform
Infectious Disease Vaccines
B4
PRISM™ Platform: physics-based drug design for oncology & infectious disease
Cancer Immunotherapy
B5
Partnerships To Address Emerging Health Threats: The urgent need for antivirals
Antiviral Therapies
Kashmira Date, Global Medical Affairs Lead - Vaccines, Johnson and Johnson Global Public Health
M3
Development of CPMV-based vaccines against cancer
New Technology
M1
Advancing R&D of long COVID & post-viral diseases through public-private partnerships
Partnerships
M2
Early development of vaccines against Nairovirus (CCHF) and Nipah Virus
Infectious Disease Vaccines
B4
Small molecule protein assembly modulators with pan-cancer therapeutic efficacy
Cancer Immunotherapy
B5
Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
Antiviral Therapies
M3
A novel molecular clamp subunit vaccine platform
New Technology
M1
The evolution of task forces & initiatives to address Hepatitis C nationally & internationally
Partnerships
M2
The Long and Winding Road to the mRNA Vaccine
New Technology
Philip Felgner, Director, Vaccine R&D Center, University of California at Irvine
M1
How can an Intellectual Property International Consortium (IPIC) benefit small biotechs? *Title TBC
Partnerships
M2
Biopharmaceutical Stocks—Out of favor, yet impressive Pipelines
Partnerships
M2
Closing Keynote Panel: The Vaccine Wars: Why vaccine mandates are more complex than you think
Keynotes
Richard Pan, Senior Policy Advisor, Board Member, Pediatrician, Former CA State Senator, Public Health Advocate, California Department of Health Care Access and Information
B4
last published: 02/Jan/24 12:15 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Lisa Purcell, Senior Vice President, Microbiology and Virology,
Vir Biotechnology, Inc.
Lisa Purcell, Ph.D. has served as the Vice President of Microbiology and Virology and head of Vir’s Saint Louis site since December 2020. Dr. Purcell’s career has been dedicated to the development of therapies within the immunology and infectious disease areas, including those for...
Philip Kim, Associate Professor,
University of Toronto
Philip M. Kim is a professor at the University of Toronto at the Donnelly Centre and the Departments of Computer Science and Molecular Genetics. In his academic research, he has been developing novel machine learning methods for protein and peptide engineering and authored over 90 publications, 7...
Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law,,
The George Washington University Law School
Richard Hughes IV, J.D., M.P.H. is a Partner at the Washington, D.C. health care law firm, Epstein, Becker & Green and a Professorial Lecturer in Law at the The George Washington University Law School. His practice, teaching and thought leadership focus on access to preventive health...
Sai Pooja Mahajan, Senior Scientist,
Prescient Design
Sai Pooja Mahajan is a Senior ML Scientist at Genentech developing biologically meaningful generative models for antibody design. She obtained her BS in Chemical Engineering from Indian Institute of Technology, Bombay and her MS and PhD in Chemical Engineering from Cornell University. During her...
Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics,
Lawrence Livermore National Laboratory
Dr. Faissol is the program lead for predictive design of biologics at Lawrence Livermore National Laboratory (LLNL) and the PI of the Generative Unconstrained Intelligent Drug Engineering program, which focuses on the computational design of antibodies and antigens. His primary research interest is ...
Phillip Lovalenti, Director,
Aridis Pharmaceuticals
Phillip M. Lovalenti, Ph.D. is Senior Director R&D at Aridis, with responsibility for product development and CMC. He is also responsible for process development, technical transfer, scale-up and validation activities of both drug substance and drug product manufacturing for all pipeline...
Joe Smyser, Chief Executive Officer,
PGP (The Public Good Projects)
Dr. Joe Smyser is the CEO of The Public Good Projects (PGP), a nonprofit organization that designs and implements large-scale behavior change programs for the public good. PGP selects its work based on three criteria: will it advance public health, will it create change at a large scale, and will...
Bali Pulendran, Professor, Department Of Pathology, Microbiology And Immunology,
Stanford University School of Medicine (USA)
Professor Bali Pulendran is the Violetta L. Horton Professor at the Stanford University School of Medicine, and a member of the Institute for Immunology, Transplantation and Infection, and the Departments of Pathology and Microbiology & Immunology at Stanford University. He is also an adjunct...
Ashish Jha, Former White House COVID-19 Response Coordinator (2022-2023); Dean,,
Brown University School of Public Health
A global leader driving public health research, policy, and practice, Dr. Jha serves as Dean of the Brown University School of Public Health. An accomplished and practicing physician, Dr. Jha is recognized globally as a trusted expert on major issues facing the nation’s health and a catalyst for...
Riley Griffin, Health Reporter,
Bloomberg
Riley Griffin is a journalist for Bloomberg News, where she reports on health policy, biosecurity and pandemic preparedness. Based in Washington, D.C., Riley covers how the US is working to counter naturally occurring, accidental and deliberate health threats. She received a Front Page Award for...
Nikki Romanik, Special Assistant to the President, Deputy Director and Chief of Staff,
Office of Pandemic Preparedness and Response Policy (OPPR), Executive Office of The President (EOP)
Nikki Romanik is the currently the Special Assistant to the President, Deputy Director and Chief of Staff for the Office of Pandemic Preparedness and Response Policy (OPPR) in the Executive Office of the President at the White House. Prior to this role, Nikki was the Senior Policy Advisor for the...
Daniel Wolfe, Branch Chief, BARDA CBRN Vaccines,
Biomedical Advanced Research And Development Authority
Dr. Wolfe currently serve as the Branch Chief for the Vaccine Program in support of the CBRN Division of the Biomedical Advanced Research and Development Authority (BARDA). In doing so, he leads the advanced development and management of complex vaccine projects targeting biological threats. The...
Dr Jay Butler, Senior Advisor for Infectious Diseases, Office of Readiness and Response,
Centers for Disease Control and Prevention
Jay C. Butler, MD is Senior Advisor for Infectious Diseases in the Office of Readiness and Response at CDC. Dr. Butler has over 30 years of experience in increasingly complex public health leadership and management positions. He graduated from North Carolina State University with a BS in...
Ali M Harandi, Lab Head, Dpt Of Microbiology And Immunology,
University of Gothenburg
Dr. Ali Harandi is currently affiliated to Sahlgrenska Academy at University of Gothenburg in Sweden and holds a visiting faculty position at Vaccine Evaluation Center, University of British Columbia in Canada. Dr. Harandi was awarded the prestigious Heine-Medin medal by European Society for...
Alejandro Cane, VP, US/IDM Vaccines and Antivirals Medical and Scientific Affairs Lead,
Pfizer
Alejandro D. Cané is a Specialist in Pediatrics and Pediatric Infectious Diseases and graduated with honors from the University of Buenos Aires, Argentina. In addition, he completed a Master’s in clinical and Pharmacological Research at the Universidad Austral, Buenos Aires, Argentina and also...
Juan José Albarrán, Chief Commercial Officer,
Q-Vant Biosciences
More than 10 years of experience in quillaja extract process development, supply chain, manufacturing, R&D and commercialization. Former Founder and Managing Director of Chile Botanics–Naturex, global leader in the Quillaja Extracts markets.
Pamela Housh, Director of Business Development,
Eyam Vaccines and Immunotherapeutics
Dr. Pamela Housh is a life sciences professional with a PhD in Microbiology and Immunology and an EMBA specialized in Executive Leadership. Her passion lies in purposeful project involvement, fostering collaboration, and nurturing impactful partnerships. With a collaborative, curious, and...
Kristyn Aalto, Chief Executive Officer,
Orlance, Inc.
Kristyn Aalto, Orlance CEO, founded Seattle-based Orlance, Inc. along with University of Washington faculty Deboral Fuller, PhD and James Mullins, PhD to develop pneumatically-delivered DNA and RNA vaccine and therapeutics that address multiple clinical and logistics needs within today’s rapidly...
Niranjan Kumar, President & Chief Executive Officer,
ABS Inc. USA
Dr. Niranjan Kumar is President & CEO of ABS Inc. USA. Dr. Kumar has over 30 years of top global biopharmaceutical companies experience with increasing roles and responsibilities. Prior to joining ABS Inc, Biotechnology company, Dr. Kumar worked for...
Michael Caldwell, Assoc VP Vaccine Research & Education,
Meharry Medical College
Dr. Caldwell is the Associate Vice President, Vaccine Research & Education at Meharry Medical College in Nashville TN. He leads the emerging partnership between Meharry and Clinical Research Associates of Nashville and is a devoted clinician and teacher. Dr. Caldwell serves as an investigator...
Daniela Weiskopf, Research Assistant Professor,
La Jolla Institute for Allergy and Immunology
Daniela has devoted her career to understanding the T-cell response to viral pathogens and relevant to human health and disease. In 2009, she received my PhD in Immunology from Innsbruck Medical University, Austria, where she performed research analyzing posttranslational modifications of...
Kathie Seley-Radtke, Professor Chemistry & Biochemistry,
University of Maryland Baltimore County
Dr. Kathie Seley-Radtke is a Professor in the Department of Chemistry & Biochemistry at the University of Maryland, Baltimore County. Her medicinal chemistry research focuses on targeting coronaviruses, filoviruses, flaviviruses among other infectious diseases, using her novel “fleximer”...
Heather Platt, Distinguished Scientist, Clinical Research (Pneumococcal Vaccines),
Merck & Co., Inc.
Heather Platt, MD, is a distinguished scientist within Merck Research Laboratories. She completed her training in Internal Medicine at Rutgers/Robert Wood Johnson Medical School, and Infectious Diseases Fellowship at New York Presbyterian/Columbia University Medical Center. Over the past 10...
Cokey Nguyen, Chief Scientific Officer,
Atara Biotherapeutics
Dr. Cokey Nguyen is a leader in the fields of cell therapy and oncology with significant experience in research and development of cell therapies as well as oncology drug discovery and development in biotech. Dr. Nguyen serves as Chief Scientific Officer at Atara, where he is focused on leading the ...
Cynthia Derdeyn, Professor, Vice Chair of Research,
University of Washington
Professor and Vice Chair of Research in the Department of Laboratory Medicine and Pathology at the University of Washington and Core Scientist in the Infectious Disease and Translational Medicine Unit of the Washington National Primate Research Center, Seattle, WA. Dr. Derdeyn uses human subjects...
Jade Benjamin-Chung, Assistant Professor of Epidemiology & Population Health,,
Stanford University
Jade Benjamin-Chung, PhD MPH, is an Assistant Professor at Stanford University in the Department of Epidemiology and Population Health and Chan Zuckerberg Biohub Investigator. She completed her PhD in Epidemiology and MA in Biostatistics at UC Berkeley. Her group conducts research to identify...
Jorge Villacian, Compound Development Leader,
Johnson & Johnson Innovation
Jorge is the Compound Development Leader for CD388 at Janssen R&D, where he has led the Janssen team in collaboration with Cidara Therapeutics to advance this compound through clinical development. Jorge has held several positions since joining Johnson and Johnson in 2006, including Chief...
Morgan Monslow, Principal Scientist, Discovery-Biology (ID-Vaccines),,
Merck & Co., Inc.
Morgan Monslow, PhD, is a principal scientist in the department of Infectious Diseases and Vaccines at Merck in West Point, PA. In her current role, she supports Merck’s early vaccine development efforts and specializes in vaccine immunology. Before joining Merck, she received her PhD in molecular...
James Wassil, Chief Operating Officer,
Vaxcyte
Jim brings extensive experience in the development and commercialization of vaccines having spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. He was responsible for the development and launch of Menveo, the meningococcal...
Lauren V Wood, Chief Medical Officer,
P.D.S. Biotechnology Corp
Dr. Wood joined PDS Biotechnology as Chief Medical Officer in February 2019. She has overall responsibility for clinical development of the novel, immune activating Verrsamuneâ platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid...
Milan Raska, Professor of Immunology at Faculty of Medicine and Dentistry,
Dept. of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc
Milan Raska completed his Ph.D. at the age of 35 years from Palacky University, Olomouc, Czech Republic. He spent his postdoctoral fellowship at the University of Alabama at Birmingham, Birmingham, AL, USA at the laboratories of prof. Mestecky and prof. Novak. Dr. Raska is currently a Professor of...
Pete Schmidt, CMO,
Invivyd
Pete is the Chief Medical Officer of Invivyd. He joined in November of 2020, first serving as the Vice President of Clinical Research before being appointed CMO in December of 2022. He brings nearly 15 years of experience in drug discovery to the team, having overseen both early and late-stage...
Ariel Weinberger, Chief Executive Officer,
Autonomous Therapeutics
Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari started Autonomous from a single bench in the Brooklyn Navy Yard in 2017, and grew the company to a team of more than 20 at Johnson & Johnson’s JLABS incubator in New York City. At JLABS, Autonomous was selected as...
Mark Esser, Vice President, Early Vaccines & Immune Therapies R&D,
Astrazeneca
Dr. Esser is Vice President of Vaccines and Immune Therapies early R&D at AstraZeneca and is accountable for overall drug discovery, translational research and clinical development of innovative medicines targeting the microbiome and infectious disease. In response to the COVID-19...
Sara Pai, Professor of Surgery,
Yale University School of Medicine
Sara Isabel Pai, MD, PhD, FACS: Dr. Pai is Professor of Surgery at Yale University School of Medicine. She graduated Summa Cum Laude from Dartmouth College with a major in Biochemistry and Molecular Biology. After graduating Dartmouth, she completed the MD/PhD program at Johns Hopkins University...
Ricardo Da Silva Antunes, Instructor, Division of Vaccine Discovery,
La Jolla Institute for Allergy and Immunology
Dr. da Silva Antunes earned his Ph.D. in Biomedical Sciences in 2010. In 2012 he moved to La Jolla Institute for Immunology. Upon connecting with Alessandro Sette's lab in 2016, he has been deciphering T-cell immune response mechanisms against several emergent pathogens relevant to worldwide...
Jonathan Low, Medical Student,
Meharry Medical College
Jonathan Low is an award-winning, published MD candidate at Meharry Medical College. He previously earned an MBA with a focus on business analytics and a MA in Biomedical Sciences. Additionally, he is a CEO of a health tech startup he co-founded last year with his colleagues Tony Vu and Jeremy...
Michael Caldwell, Assoc VP Vaccine Research & Education,
Meharry Medical College
Dr. Caldwell is the Associate Vice President, Vaccine Research & Education at Meharry Medical College in Nashville TN. He leads the emerging partnership between Meharry and Clinical Research Associates of Nashville and is a devoted clinician and teacher. Dr. Caldwell serves as an investigator...
Daniela Weiskopf, Research Assistant Professor,
La Jolla Institute for Allergy and Immunology
Daniela has devoted her career to understanding the T-cell response to viral pathogens and relevant to human health and disease. In 2009, she received my PhD in Immunology from Innsbruck Medical University, Austria, where she performed research analyzing posttranslational modifications of...
Zhuoming Liu, Instructor in Molecular Microbiology,
Washington University School of Medicine in St. Louis
Zhuoming (Joemin) earned his Ph.D in 2015 at The University of Tokyo in Japan, where he studied molecular mechanisms of replication of Herpes Simplex Virus 1. After completing his Ph.D, he joined Dr. Sean Whelan lab as a postdoc to study host factors required for viral entry. Currently, he works as ...
Javad Aman, President & CSO,
AbVacc Inc.
Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, infectious disease, and vaccine and immunotherapeutics development. He received his M.S. in Pharmacy from University of Frankfurt and Ph.D. in molecular immunology from...
Noam Auslander, Assistant Professor, Molecular & Cellular Oncogenesis Program,
The Wistar Institute
Noam Auslander, PhD, is an assistant professor in the Molecular & Cellular Oncogenesis Program at the Wistar Institute. Before joining the Wistar institute, she completed a Bachelor of Science degree in computer science and in biology at Tel Aviv University, Israel, then earned her doctoral...
Pratima Rawat, Senior Scientist,
Microbiologics
Dr Pratima Rawat is a research scientist with over 12 years of multidisciplinary experience in preclinical and clinical research in infectious disease biology, virology, HIV biology and central nervous system inflammation fields. She is interested in translating her research training and experience ...
William Smith, MD/PI,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Heinz Lubenau, Chief Drug Development Officer,
NEC OncoImmunity AS
Heinz Lubenau is currently Chief Executive Officer and co-founder of NEC Bio Therapeutics where he is leading the AI-empowered personalized neoantigen drug development which includes the proprietary product NECVAX-NEO1 and the clinical collaboration with Transgene’s MyVac product. He has been...
Sam Lee, President & Co-Chief Executive Officer,
Cocrystal Pharma, Inc.
Sam Lee, Ph.D., is President, Co-CEO and co-founder of Cocrystal Pharma Inc., Bothell, Washington, founded in 2007. Cocrystal Pharma Inc. (NASDAQ: COCP) is developing novel small molecule antivirals for the treatment of COVID-19, Influenza, Norovirus, and Hepatitis C. He served on the Board of...
Renata Varnaite, Field Application Specialist, North America,
Mabtech
Renata Varnaite, PhD, is a field application specialist at Mabtech, a Swedish biotech company specializing in monoclonal antibody development, immunoassays, and advanced ELISpot and FluoroSpot instruments. Before joining Mabtech, Renata completed her PhD at Karolinska Institutet, Sweden and her...
Kevin Killeen, CSO,
Matrivax
Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr Killeen’s experience includes identifying and leading the in-licensing effort of the rotavirus vaccine...
Paul Hallenbeck, Founder And Chief Executive Officer,
Seneca Therapeutics
Dr Hallenbeck is the founder & CEO of Seneca Therapeutics. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immunotherapeutics R&D. As the sole founder of Neotropix he raised $30M in VC, then successfully ...
Nigel Temperton, Professor,
University of Kent
Nigel obtained his BSc (Hons) in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine...
Tammy Boyce, Executive Director, Clinical Operations,
Dynavax Technologies
Tammy Boyce is Executive Director, Clinical Operations at Dynavax where she and her team are responsible for translating the company’s clinical development strategies into effective clinical trials in support of its mission to help protect the world against infectious disease. She is responsible...
Don Diamond, Professor, Department Of Hematology And Hematopoietic Cell Transplantation,
City of Hope Comprehensive Cancer Center
Dr. Diamond received his A.B. from Harvard University and published a seminal paper on RNA as an undergraduate that has over 3500 citations. A graduate of Harvard Medical School with a Ph.D, was followed by a 2-year fellowship with Dr. Susumu Tonegawa (Nobel Laureate, 1987). He obtained an LLS...
John Bilello, Senior Director, Biology,
Gilead Sciences
John Bilello leads the Respiratory and Emerging Viruses group at Gilead Sciences, Inc., focusing on coronavirus antiviral drug discovery in addition to advancing other respiratory virus programs to the clinic. Dr. Bilello supervised the establishment of two successive BSL3 labs at Gilead to address ...
Niranjan Kumar, President & Chief Executive Officer,
ABS Inc. USA
Dr. Niranjan Kumar is President & CEO of ABS Inc. USA. Dr. Kumar has over 30 years of top global biopharmaceutical companies experience with increasing roles and responsibilities. Prior to joining ABS Inc, Biotechnology company, Dr. Kumar worked for...
Morgan Monslow, Principal Scientist, Discovery-Biology (ID-Vaccines),,
Merck & Co., Inc.
Morgan Monslow, PhD, is a principal scientist in the department of Infectious Diseases and Vaccines at Merck in West Point, PA. In her current role, she supports Merck’s early vaccine development efforts and specializes in vaccine immunology. Before joining Merck, she received her PhD in molecular...
James Wassil, Chief Operating Officer,
Vaxcyte
Jim brings extensive experience in the development and commercialization of vaccines having spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. He was responsible for the development and launch of Menveo, the meningococcal...
Kevin Killeen, CSO,
Matrivax
Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr Killeen’s experience includes identifying and leading the in-licensing effort of the rotavirus vaccine...
Steve Thorne, Chief Scientific Officer,
Kalivir Immunotherapeutics
Stephen Thorne co-founded Kalivir in 2019 and currently serves as Chief Scientific Officer. He is a leader in the field of oncolytic viral immunotherapy and previously co-founded Western Oncolytics, BioEclipse and Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials.
...
Vel Murugan, Associate Director of Research,
ASU Biodesign Institute
Dr. Vel Murugan is a trained molecular cell biologist with extensive experience in studying cell cycle regulation, cancer biology, vaccine discovery and development. Dr. Murugan brings with him a wealth of experience from his time in both industry as well as academic institutions. Dr. Murugan...
Peter Goldstein, Executive Director, Research and Development,
ILIAD Biotechnologies
Peter Goldstein, Executive Director of Vaccine Platform Development. Peter has 18 years of experience managing multidisciplinary scientific and technical programs. He plays a central role in management of ILiAD’s assay development, clinical serology, and Quality Management System, and is...
Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics,
Lawrence Livermore National Laboratory
Dr. Faissol is the program lead for predictive design of biologics at Lawrence Livermore National Laboratory (LLNL) and the PI of the Generative Unconstrained Intelligent Drug Engineering program, which focuses on the computational design of antibodies and antigens. His primary research interest is ...
Lisa Purcell, Senior Vice President, Microbiology and Virology,
Vir Biotechnology, Inc.
Lisa Purcell, Ph.D. has served as the Vice President of Microbiology and Virology and head of Vir’s Saint Louis site since December 2020. Dr. Purcell’s career has been dedicated to the development of therapies within the immunology and infectious disease areas, including those for...
Mark Esser, Vice President, Early Vaccines & Immune Therapies R&D,
Astrazeneca
Dr. Esser is Vice President of Vaccines and Immune Therapies early R&D at AstraZeneca and is accountable for overall drug discovery, translational research and clinical development of innovative medicines targeting the microbiome and infectious disease. In response to the COVID-19...
Pete Schmidt, CMO,
Invivyd
Pete is the Chief Medical Officer of Invivyd. He joined in November of 2020, first serving as the Vice President of Clinical Research before being appointed CMO in December of 2022. He brings nearly 15 years of experience in drug discovery to the team, having overseen both early and late-stage...
Flonza Isa, Associate Medical Director,
Regeneron Pharmaceuticals
Board-certified physician-scientist with an extensive background in the fields of internal medicine and infectious disease. Research background has largely focused on utilizing new technologies to improve diagnostics. Specialties include: mass spectrometry, translational laboratory research, and...
Karen Martins, Chief, Antivirals and Antitoxins Division of CBRN Countermeasures,
Biomedical Advanced Research and Development Authority (BARDA)
Dr. Karen Martins is the Branch Chief for Antivirals and Antitoxins (AVAT) at the Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS). The AVAT program supports...
Dennis Hruby, Chief Scientific Officer,
SIGA Technologies, Inc.
Dennis E. Hruby, Ph.D., Executive Vice President and Chief Scientific Officer Dennis E. Hruby, Ph.D., has been with SIGA Technologies since January 1996, serving as the Chief Scientific Officer since June 2000. Dr. Hruby received his Ph.D. in Microbiology from the University of Colorado Medical...
John Dubinion, Pharmacologist,
FDA
John Dubinion is a Master Pharmacologist in the Division of Pharm/Tox for Infectious Diseases (Office of Infectious Diseases/Office of New Drugs/Center for Drug Evaluation and Research/FDA). He reviews nonclinical regulatory submissions for antiviral drugs. He obtained a Ph.D. in Pharmacology at...
Dan Sanford, Research Leader,
Battelle
Dr. Daniel Sanford is a Research Leader at Battelle’s Biomedical Research Center (BRC). He has served as Study Director (SD) on more than seventy studies conducted at the Battelle high-containment laboratory over the past sixteen years, with a focus on bacterial/viral pathogenesis, MCM...
Danny Conrad, Graduate Student Researcher,
University of California San Francisco
Danny was raised in the Bay Area and completed his B.S. in Cell & Developmental Biology at UCSB, where he worked with C. elegans in the Rothman Lab. From there he returned to the Bay Area to work on his Ph.D. at UCSF in the Gartner Lab. Since joining, Danny has worked on various projects...
Jeffrey Skolnik, Senior Vice President Of Clinical Development,
Inovio Pharmaceuticals
Dr. Skolnik leads INOVIO’s clinical development programs, focusing on HPV and immuno-oncology DNA medicines. He is a key member of the leadership team overseeing these global clinical assets. Dr. Skolnik has held several leadership positions in Clinical Development and Medical Affairs for...
James Crowe, Director,
Vanderbilt Vaccine Center
Dr. James Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging...
Arlene Joyner, Deputy Assistant Secretary,
HHS/ASPR
Ms. Arlene Joyner is the Deputy Assistant Secretary and Director, Industrial Base Management and Supply Chain for the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). In this role, she is responsible for leading HHS efforts ...
Varun Kapoor, Director, Translational Medicine,
Coherus BioSciences
Varun Kapoor, Ph.D., is the Director of Translational Medicine at Coherus Biosciences. He brings in more than 10 years of research and development experience in immuno-oncology therapies to help establish and advance translational and biomarker strategies. He completed his post-doctoral training in ...
Matt Davis, Senior Director, Molecular Biology and Sequencing,
Gritstone Bio
Matthew Davis PhD joined Gritstone Bio (NASDAQ: GRTS) in 2015 and is currently the Senior Director of Molecular Biology and Sequencing responsible for various neoantigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio...
Estevan Kiernan, Associate Director, Emerging Clinical Applications-Oncology,
Illumina
Estevan Kiernan has worked in infectious disease, genetic disease and oncology molecular diagnostics 15+ years at leading biotech companies including Thermo Fisher/Life Technologies and Abbott. For the Last 7 years he has worked at Illumina to identify future clinical applications and work globally ...
Steven Reed, Chief Executive Officer,
HDT Bio Corp
Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...
Robert Shoemaker, Chief, Chemopreventive Agent Development Research Group,
National Cancer Institute
Dr. Robert Shoemaker obtained his Ph.D. in human genetics from the Graduate School of Public Health of the University of Pittsburgh in 1975. Following postdoctoral experience at the Armed Forces Institute of Pathology he moved to the Children's Hospital Medical Center of Akron. His research on...
Zelanna Goldberg, Chief Medical Officer,
Replicate Bioscience, Inc.
Dr. Zelanna Goldberg, the Chief Medical Officer at Replicate Bioscience, is a radiation oncologist with over 20 years’ experience in drug development and industry leadership. Before joining Replicate, she was Chief Medical Officer at Alpine Immune Sciences and, before Alpine, she was Senior Vice...
Joshua Dinapoli, Global Project Head mRNA Platform Development,
Sanofi Pasteur
Joshua DiNapoli received his PhD in Microbiology and Immunology from the University of Rochester in 2005, where he performed work in the lab of Dr. Robert C. Rose on virus-like particle vaccines against human papillomavirus. He went on to perform his post-doctoral work in the lab of Dr. Peter...
Ali M Harandi, Lab Head, Dpt Of Microbiology And Immunology,
University of Gothenburg
Dr. Ali Harandi is currently affiliated to Sahlgrenska Academy at University of Gothenburg in Sweden and holds a visiting faculty position at Vaccine Evaluation Center, University of British Columbia in Canada. Dr. Harandi was awarded the prestigious Heine-Medin medal by European Society for...
Darrick Carter, Chief Executive Officer, PAI Life Sciences, Co-Founder & Advisor,
HDT Bio Corp
Dr. Carter is CEO of PAI Life Sciences Inc. and Co-Founder and Senior Advisor to HDT Bio Corp, a Seattle, WA based startup company developing vaccines and immune therapies. He is a biochemist/biophysicist and has founded five biotech companies. In 1998 he led the first new recombinant tuberculosis...
Xicheng Sun, Vice President, Chemistry & Manufacturing,
Crestone, Inc.
Xicheng Sun, Ph.D. Vice President, Chemistry & Manufacturing at Crestone In. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals, overseeing internal and external activities from medicinal chemistry, chemical...
Benedetta Pelosi, Scientific Consultant,
Giant
BENEDETTA PELOSI is an Italian researcher in molecular biology formed between University of Florence and Sweden. In particular, she attended the Master program ‘‘Plant and Forest Biotechnology’’ at Umeå University from 2014 to 2015. Subsequently she has been in a Molecular Biosciences program at...
Vic Suarez, COL (Ret), US Army; Founder & Senior Partner,
BluZoneBio
Vic Suarez, Colonel (Ret), US Army, MS, PMP, CMRP is the Founder and Principal Growth Partner of Blu Zone Bioscience & Supply Chain Solutions, LLC. Blu Zone Bio assists biotechnology and life science supply chain organizations accelerate growth and expand domestic biomanufacturing through...
Alejandro Cane, VP, US/IDM Vaccines and Antivirals Medical and Scientific Affairs Lead,
Pfizer
Alejandro D. Cané is a Specialist in Pediatrics and Pediatric Infectious Diseases and graduated with honors from the University of Buenos Aires, Argentina. In addition, he completed a Master’s in clinical and Pharmacological Research at the Universidad Austral, Buenos Aires, Argentina and also...
Lei Zheng, Co-director, Pancreatic Cancer Precision Medicine Center of Excellence Program,
Johns Hopkins Medicine
Lei Zheng, M.D., Ph.D. is Professor of Oncology and Surgery at the Johns Hopkins University School of Medicine. He is the Cancer Center and the Department of Oncology’s Assistant Director for Translational Research and Associate Cancer Center Director for Precision Medicine. He co-leads the...
Xicheng Sun, Vice President, Chemistry & Manufacturing,
Crestone, Inc.
Xicheng Sun, Ph.D. Vice President, Chemistry & Manufacturing at Crestone In. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals, overseeing internal and external activities from medicinal chemistry, chemical...
Scott Balsitis, Senior Director, Hepatitis B Cure Research,,
Gilead Sciences
Dr. Balsitis is Head of HBV Cure Research at Gilead Sciences. He has over 20 years of experience in the pathogenesis and immunology of chronic viral infections, and has spent the last 10 years researching and developing novel agents designed to deliver functional cures for chronic hepatitis B.
Jay Lieberman, VP of Clinical Development,
Meissa Vaccines
Jay M. Lieberman, MD is Vice President of Clinical Development at Meissa Vaccines. Before joining Meissa, he was a Director of Medical Affairs at ICON plc (formerly PRA Health Sciences), where he served as a Medical Monitor and Therapeutic Expert for clinical trials of a variety of vaccines and...
Pravin Kaumaya, Professor of Microbiology and Immunology,
Indiana University School of Medicine
Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as...
Matt Davis, Senior Director, Molecular Biology and Sequencing,
Gritstone Bio
Matthew Davis PhD joined Gritstone Bio (NASDAQ: GRTS) in 2015 and is currently the Senior Director of Molecular Biology and Sequencing responsible for various neoantigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio...
Takeki Uehara, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division,
Shionogi & Co., Ltd
Dr. Takeki Uehara received his DVM degree at the Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan, in 2002. After his graduation, he joined Shionogi & Co., Ltd. as a research scientist. In 2008 he received his PhD degree of...
Ju-Tao Guo, Vice President, Research Programs, Baruch S. Blumberg Institute;CSO;,
Merlin Biotech
Dr. Guo is Senior Vice President for Research and the W. Thomas London Professor at the Baruch S. Blumberg Institute. He has been working on molecular virology and antiviral research of hepatitis viruses, flaviviruses and human coronaviruses for decades. Dr. Guo’s current research efforts are...
Jaroslav Turánek, Head of Research and Development,
NEXARS
Jaroslav Turánek is professor of medical immunology and research professor in the field medical nanotechnologies and molecular biological sciences. After studying biochemistry at the Masaryk University in Brno, he devoted himself to the development of immunopharmacology and immunotherapy in the...
Daniel Ellis, Senior Scientist, Computational Discovery,
Icosavax, Inc.
At Icosavax, Dan focuses on structure-based antigen design for multiple vaccine candidates. Prior to Icosavax, Dan completed his PhD at the Institute for Protein Design at the University of Washington, where he helped design and develop the two-component VLP technology used by Icosavax and further...
Don Diamond, Professor, Department Of Hematology And Hematopoietic Cell Transplantation,
City of Hope Comprehensive Cancer Center
Dr. Diamond received his A.B. from Harvard University and published a seminal paper on RNA as an undergraduate that has over 3500 citations. A graduate of Harvard Medical School with a Ph.D, was followed by a 2-year fellowship with Dr. Susumu Tonegawa (Nobel Laureate, 1987). He obtained an LLS...
Ramji Srinivasan, Chief Executive Officer,
Teiko Bio Inc.
Ramji is cofounder and CEO of teiko.bio. Teiko’s mission is to make immune profiling a reality for clinical trials, and eventually for patients. They are making that mission happen by performing deep immune characterization using single-cell mass cytometry.Their team includes 12 PhD-trained...
Tong-Ming Fu, CSO infectious Diseases,
IGM Infectious Disease
Dr. Tong-Ming Fu is currently the CSO for Infectious Diseases at IGM Biosciences, INC. He spent over two decades at Merck Research Laboratories, Merck and Co., Inc., where he contributed to many novel vaccine programs, including adenovirus vector HIV-1 vaccines and influenza M2 peptide-conjugate...
John Tavis, Professor of Molecular Microbiology and Immunology,
St Louis University School Of Medicine
John Tavis, Ph.D., is a Professor of Molecular Virology at Saint Louis University and Director of the Saint Louis University Institute for Drug and Biotherapeutic Innovation. He received his doctorate in molecular virology from Penn State University in 1990 and did postdoctoral studies in molecular ...
Marek Drozdz, Director of Research,,
Renbio
Marek Drozdz, PhD, has over 15 years of experience investigating cellular processes in both physiological and disease states. At RenBio he leads research efforts for the clinical advancement of MYO Technology™. Marek received a Ph.D. in Pathology from University of Oxford, and completed a...
Jacob Glanville, Chief Executive Officer,
Centivax
Jacob Glanville is an serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the...
Danny Liaw, Senior Principal Scientist,
Merck
Danny Liaw is a member of the Oncology Early Clinical Development organization at Merck. He has 15+ years industry experience in multiple therapeutic areas, starting at Bristol-Myers Squibb (BMS) where he was on the clinical development team for the oral factor Xa inhibitor, Eliquis, and led three...
Christine Moussion, Senior Principal Scientist and Group Head,
Genentech
Dr. Moussion received her PhD from the University of Toulouse (France) where she studied the role of Dendritic cells in the control of lymphocyte migration from blood to lymph node in the lab of Jean-Philippe Girard at IPBS. She then moved to IST Austria in Vienna as a Postdoctoral fellow in the...
Ted Daley, Chief Executive Officer,
Selva Therapeutics
Before founding Selva, Ted was an Entrepreneur in Residence at University of California, San Diego. Previously he was President and Chief Business Officer for Raptor Pharmaceuticals. He joined Raptor through its acquisition of Convivia, Inc., which he founded. Ted was also co-founder and Chief...
Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Ed Kelley, Chief Global Health Officer,
ApiJect
Dr. Kelley holds the position of Chief Global Health Officer at ApiJect Systems, a US-based medical technology company with a core mission to enhance the safety and affordability of vaccines and injectable medications worldwide. Before assuming his current role, Dr. Kelley occupied the role of...
Stephen Albert Johnston, CEO,
CALVIRI
Stephen Albert Johnston is the inventor of Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell (iCx), Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in...
Joseph Dolina, Senior Scientist,
Pfizer
Dr. Dolina joined Pfizer in 2019 focused on developing first-in-class CD8+ T cell-mediated cancer immunotherapies. He holds dual B.S. degrees in Biology and Chemistry from The College of New Jersey, an M.S. in Biomedical Sciences from the University of Medicine and Dentistry of New Jersey, and a...
Andrew Lee, Vice President, Program Executive,
Vir Biotechnology, Inc.
Andy Lee, M.D., has been Vice President and Program Executive for the hepatitis program at Vir since January 2020. Prior to joining Vir, Dr. Lee led development of new vaccines and monoclonal antibodies in the department of Vaccines Clinical Research at Merck, including a pediatric hexavalent...
Jaime Flores-Riveros, CSO,
Amerstem
Dr. Flores-Riveros completed his PhD and postdoctoral studies on molecular mechanisms of insulin signal transduction and regulation of glucose transport at the Johns Hopkins University School of Medicine in Baltimore, MD. He then joined the West Haven Research Center from Bayer Pharmaceuticals as...
Jay Evans, Chief Scientific and Strategy Officer,
Inimmune
Dr. Evans is the President, Chief Executive Officer and Co-Founder of Inimmune Corp. Dr. Evans is also Director of the Center for Translational Medicine at the University of Montana and a Research Professor in the Division of Biological Sciences.
He has over 20 years’ experience in the...
Steven Reed, Chief Executive Officer,
HDT Bio Corp
Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...
Darrick Carter, Chief Executive Officer, PAI Life Sciences, Co-Founder & Advisor,
HDT Bio Corp
Dr. Carter is CEO of PAI Life Sciences Inc. and Co-Founder and Senior Advisor to HDT Bio Corp, a Seattle, WA based startup company developing vaccines and immune therapies. He is a biochemist/biophysicist and has founded five biotech companies. In 1998 he led the first new recombinant tuberculosis...
Jeffrey Nielsen, Vice President of Discovery,
Eradivir, Inc.
Dr. Jeffery Nielsen is vice president of discovery at Eradivir, overseeing the early discovery efforts for the pipeline of Eradivir. He has spent the last 11 years on early drug discovery and development. He is trained both as a chemist and a biologist using an interdisciplinary approach to design...
Timur Yarovinsky, VP of Discovery, Director of Immunology,
CaroGen Corporation
Dr. Timur Yarovinsky is Vice President of Discovery at CaroGen Corporation. Prior to CaroGen, Dr. Yarovinsky worked as a Research Scientist at Yale University and the University of Iowa. He holds M.D. and Ph.D. from Russian State Medical University
Don Loveday, Head Of Business Development,
SPI Pharma Inc
Don has 20 years of experience in the pharma and medical device industry. Don joined SPI Pharma in January 2020 as Global Business Development Manager. Before joining SPI Pharma, Don worked for Celanese as their Global Business Director. Prior to this, Don led business development for the...
Stephanie Noviello, CMO,
ILIAD Biotechnologies
Stephanie Noviello, M.D., M.P.H., Chief Medical Officer. Stephanie worked previously at Novartis as Senior Global Program Clinical Lead for assets in Immunology and skeletal Ddseases, submitting for multiple indications, creating clinical development plans for various assets and running a trial in...
Aida Cremesti, Senior Technology Transfer Specialist, Licensing, Collaborations, Clinical Trials, Patenting,
National Cancer Institute
Dr. Aida Cremesti is a senior technology transfer manager NIH’s Technology Transfer Center where she leverages her expertise in scientific research, business development, and intellectual property to support technology development and commercialization efforts at NCI. Her business development role...
Amy Rappaport, Director,
Gritstone Bio
Amy Rappaport is the Senior Director of Translational Immunology at Gritstone bio., leading preclinical vaccine development for both oncology and infectious disease indications, including the advancement and optimization of Gritstone’s self-amplifying mRNA vaccines. She received her PhD in Cancer...
Connie Tat, Senior Medical Science Director,
Genentech
Connie has over 8 years of diverse experiences in the biotech/pharma industry in the US and globally in Medical Affairs, Clinical Development, and Commercial. She is currently a Senior Medical Science Director in Oncology in Medical Affairs at Genentech, where she partners closely with the Product ...
Danny Liaw, Senior Principal Scientist,
Merck
Danny Liaw is a member of the Oncology Early Clinical Development organization at Merck. He has 15+ years industry experience in multiple therapeutic areas, starting at Bristol-Myers Squibb (BMS) where he was on the clinical development team for the oral factor Xa inhibitor, Eliquis, and led three...
Jeffrey Skolnik, Senior Vice President Of Clinical Development,
Inovio Pharmaceuticals
Dr. Skolnik leads INOVIO’s clinical development programs, focusing on HPV and immuno-oncology DNA medicines. He is a key member of the leadership team overseeing these global clinical assets. Dr. Skolnik has held several leadership positions in Clinical Development and Medical Affairs for...
Shizuko Sei, Co-Chief, Chemopreventive Agent Development,,
National Cancer Institute - NIH
Dr. Shizuko Sei (formerly Shizuko Aoki) is a medical officer with over 27 years of translational and clinical research experience in the field of cancer and AIDS. After completing her pediatric oncology fellowship at NCI Center for Cancer Research (CCR), she held various positions in the CCR and...
David Martin, CEO,
TrippBio
Dr. David E. Martin is the President and CEO of TrippBio, Inc. a clinical development-stage company developing antiviral therapies for the treatment of respiratory infections. Dr. Martin has more than 30 years of hands-on drug development experience across the spectrum of drug...
Scott Balsitis, Senior Director, Hepatitis B Cure Research,,
Gilead Sciences
Dr. Balsitis is Head of HBV Cure Research at Gilead Sciences. He has over 20 years of experience in the pathogenesis and immunology of chronic viral infections, and has spent the last 10 years researching and developing novel agents designed to deliver functional cures for chronic hepatitis B.
John Tavis, Professor of Molecular Microbiology and Immunology,
St Louis University School Of Medicine
John Tavis, Ph.D., is a Professor of Molecular Virology at Saint Louis University and Director of the Saint Louis University Institute for Drug and Biotherapeutic Innovation. He received his doctorate in molecular virology from Penn State University in 1990 and did postdoctoral studies in molecular ...
Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Andrew Lee, Vice President, Program Executive,
Vir Biotechnology, Inc.
Andy Lee, M.D., has been Vice President and Program Executive for the hepatitis program at Vir since January 2020. Prior to joining Vir, Dr. Lee led development of new vaccines and monoclonal antibodies in the department of Vaccines Clinical Research at Merck, including a pediatric hexavalent...
Ju-Tao Guo, Vice President, Research Programs, Baruch S. Blumberg Institute;CSO;,
Merlin Biotech
Dr. Guo is Senior Vice President for Research and the W. Thomas London Professor at the Baruch S. Blumberg Institute. He has been working on molecular virology and antiviral research of hepatitis viruses, flaviviruses and human coronaviruses for decades. Dr. Guo’s current research efforts are...
Sue Behrens, President, SB Consulting, Professor in Bioprocessing, Director, Amgen Bioprocessing Center,
Keck Graduate Institute of Applied Life Sciences
Dr. Sue Behrens is George B. and Joy Rathmann Professor in Bioprocessing and Director of the Amgen Bioprocessing Center at Keck Graduate Institute (KGI) in Claremont, CA. Until July-2023, she also served as Program Director for the Masters of Engineering in Biopharmaceutical Processing which...
Estevan Kiernan, Associate Director, Emerging Clinical Applications-Oncology,
Illumina
Estevan Kiernan has worked in infectious disease, genetic disease and oncology molecular diagnostics 15+ years at leading biotech companies including Thermo Fisher/Life Technologies and Abbott. For the Last 7 years he has worked at Illumina to identify future clinical applications and work globally ...
Taylor Sexton, Executive Director,
Medical Countermeasures Coaltion
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
Ekaterina Vert-Wong, Vice President, Portfolio & Alliance Management,
Sabin Vaccine Institute
Ekaterina Vert-Wong is the vice president of Research & Development Operations at the Sabin Vaccine Institute. In this role, she leads operational, organizational and alliance management functions. Since joining Sabin in 2021, she oversees R&D programs planning and execution and leads the...
Nina Malkevich, Senior Director and Product Development Lead - Emerging Infectious Diseases,
International AIDS Vaccine Initiative
Prior to IAVI, Nina worked as a senior nonclinical Subject Matter Expert in the Nonclinical Division at BARDA supporting SARS-CoV-2, Ebola, pandemic flu programs focusing on animal model development and testing Medical Countermeasures (MCMs). Nina has 15 years of experience in scientific leadership ...
Daniel Wolfe, Branch Chief, BARDA CBRN Vaccines,
Biomedical Advanced Research And Development Authority
Dr. Wolfe currently serve as the Branch Chief for the Vaccine Program in support of the CBRN Division of the Biomedical Advanced Research and Development Authority (BARDA). In doing so, he leads the advanced development and management of complex vaccine projects targeting biological threats. The...
Riley Griffin, Health Reporter,
Bloomberg
Riley Griffin is a journalist for Bloomberg News, where she reports on health policy, biosecurity and pandemic preparedness. Based in Washington, D.C., Riley covers how the US is working to counter naturally occurring, accidental and deliberate health threats. She received a Front Page Award for...
Ariel Weinberger, Chief Executive Officer,
Autonomous Therapeutics
Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari started Autonomous from a single bench in the Brooklyn Navy Yard in 2017, and grew the company to a team of more than 20 at Johnson & Johnson’s JLABS incubator in New York City. At JLABS, Autonomous was selected as...
Vic Suarez, COL (Ret), US Army; Founder & Senior Partner,
BluZoneBio
Vic Suarez, Colonel (Ret), US Army, MS, PMP, CMRP is the Founder and Principal Growth Partner of Blu Zone Bioscience & Supply Chain Solutions, LLC. Blu Zone Bio assists biotechnology and life science supply chain organizations accelerate growth and expand domestic biomanufacturing through...
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships,
Moderna
Hamilton Bennett (she/her) is the Senior Director of Vaccine Access and Partnerships at Moderna, a company pioneering messenger RNA (mRNA) therapeutics and vaccines. Hamilton maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed...
Becky Pferdehirt, Partner,
Andreessen Horowitz
Becky Pferdehirt is an investing partner on the a16z Bio + Health team. Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen...
Bernd van Buuren, Chief Executive Officer,
Protinhi Therapeutics
Bernd co-founded Protinhi in 2013 and became CEO at the start of Protinhi’s operational activities in 2016. In that time he grew the company from 1 to 10 people and attracted a world leading scientific advisory board to Protinhi. Bernd has more than 25 years experience in Life Sciences R&D...
Allan Gobbs, Managing Partner,
Atem Capital
Anton Gopka is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Gopka had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at...
Taylor Sexton, Executive Director,
Medical Countermeasures Coaltion
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
Nina Malkevich, Senior Director and Product Development Lead - Emerging Infectious Diseases,
International AIDS Vaccine Initiative
Prior to IAVI, Nina worked as a senior nonclinical Subject Matter Expert in the Nonclinical Division at BARDA supporting SARS-CoV-2, Ebola, pandemic flu programs focusing on animal model development and testing Medical Countermeasures (MCMs). Nina has 15 years of experience in scientific leadership ...
Varun Kapoor, Director, Translational Medicine,
Coherus BioSciences
Varun Kapoor, Ph.D., is the Director of Translational Medicine at Coherus Biosciences. He brings in more than 10 years of research and development experience in immuno-oncology therapies to help establish and advance translational and biomarker strategies. He completed his post-doctoral training in ...
Sebastian Goy, COO,
EBViously (in formation)
Dr. Sebastian Goy will act as Chief Operational Officer of EBViously, a planned preclinical start-up company focusing on a novel virus-like particle based vaccine to prevent Epstein-Barr-associated disease.He has worked in the field of new drug candidates, their preclinical development and...
Taylor Sexton, Executive Director,
Medical Countermeasures Coaltion
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
John Bilello, Senior Director, Biology,
Gilead Sciences
John Bilello leads the Respiratory and Emerging Viruses group at Gilead Sciences, Inc., focusing on coronavirus antiviral drug discovery in addition to advancing other respiratory virus programs to the clinic. Dr. Bilello supervised the establishment of two successive BSL3 labs at Gilead to address ...
Ann Ginsberg, Deputy Director,
B.M.G.F.
Dr. Ann Ginsberg is Deputy Director, TB Vaccines at the Bill & Melinda Gates Foundation. She has been engaged in TB drug and vaccine development for over twenty years, leading programs in the government, for-profit and not-for-profit sectors.
Wendy Chen, Senior Scientist,
Amgen
Dr. Chen is currently a scientist in the In Vivo Pharmacology / Oncology department at Amgen, at the South San Francisco Site. Amgen's mission is to serve patients and the in vivo pharmacology group is specifically responsible for designing, generating and communicating pharmacology and...
Subodh Samrat, Research Scientist III,
University of Arizona
Subodh received his Ph.D. in Viral Immunology from the University of Alberta, Edmonton, Alberta, Canada. His Ph.D. thesis focused on the modulation of the immune response by Hepatitis C virus antigens.Furthermore, he moved to Wayne State University, Detroit, Michigan, USA, to continue as a...
Jiang Zhu, CSO,
Uvax Bio
Trained as a biophysicist, Jiang conducts research in microbiology, immunology, and vaccinology. His laboratory at Scripps Research is developing single-component, multilayered, self-assembling protein nanoparticle (SApNP) vaccines for viral and non-viral pathogens. They currently work on...
Daniel Wolfe, Branch Chief, BARDA CBRN Vaccines,
Biomedical Advanced Research And Development Authority
Dr. Wolfe currently serve as the Branch Chief for the Vaccine Program in support of the CBRN Division of the Biomedical Advanced Research and Development Authority (BARDA). In doing so, he leads the advanced development and management of complex vaccine projects targeting biological threats. The...
Jason E Comer, Assistant Professor, Department Microbiology And Immunology,
University of Texas Medical Branch
Dr. Comer is an Associate Professor in the Department of Microbiology and Immunology and a Study Director in the Institutional Office of Regulated Nonclinical Studies at the University of Texas Medical Branch at Galveston. Dr. Comer is interested in the development of infectious disease models...
Bradlee Heckmann, Assistant Prof, USF Health Neuroscience Institute & Morsani College of Medicine; Scientific Co-Founder,
Asha Therapeutics
Dr. Heckmann is a scientific co-founder and Chief Scientific Officer of Asha Therapeutics. He has an extensive background in neuroimmunology/neurobiology, metabolic biology, and cancer biology. He received his B.S. degree from the University of Kentucky where he studied Biology and Chemical...
Steven King, President and Chief Executive Officer,
Mosaic Immunoengineering
Mr. King has more than 15 years as CEO and BOD member of NASDAQ biotechnology company Peregrine Pharmaceuticals. He helped raise over $250M to advance the company's lead product and grow their CDMO business. Steve led the Peregrine team to advance the lead product from discovery through phase...
Oved Amitay, CEO,
SOLVE M.E.
Oved Amitay is a pharmacologist by training, a drug-developer by trade, and a patient-advocate by choice. He serves as President and Chief Executive Officer at the Solve ME/CFS Initiative- a national organization devoted to making Myalgic Encephalomyelitis (also known as chronic fatigue syndrome or ...
Jesse Erasmus, Director,
HDT Bio Corp
Dr. Jesse Erasmus is the Director of Virology at HDT Bio, a startup company in Seattle, WA. Jesse received his PhD from the University of Texas Medical Branch and completed his postdoctoral training at the Infectious Disease Research Institute and the University of Washington. His research is...
Anuradha Lingappa Esq., Director, Oncology,
Prosetta Biosciences
Anuradha Lingappa is an attorney and biochemist at Prosetta Biosciences, Inc. She manages the oncology drug discovery program at Prosetta, which recently won the ARPA-H Dash to Accelerate Health Outcomes innovation contest.
Marwah Karim, Postdoctoral Scholar,
Stanford University School of Medicine (USA)
Marwah Karim, Ph.D., is a postdoctoral fellow at Professor Shirit Einav’s lab at Stanford University School of Medicine. Prior to joining the Einav lab, she completed her Bachelor of Science degree in genetic engineering and biotechnology at the University of Dhaka, Bangladesh, then earned her...
Keith Chappell, Senior Research Fellow,
The University of Queensland
A/Prof Keith Chappell is a Molecular Virologist whose research is focused on structure-based design of vaccines for medically important viruses. Keith is a group leader within the University of Queensland as well as lead scientific advisor to Vicebio Ltd. Keith is one of the inventors of the...
William Remak, Senior Advisor,
Global Immunization Action Network Team
William (Bill) Remak, MS, MPH, founder and CEO of the California Hepatitis C Task Force and the Global Immunization Action Network Team (GIANT) former UCSF faculty, a prominent healthcare and health policy journalist and scientist with lived experience as a cancer and two-time liver transplant...
Barry Datlof, Chief, Business Development and Commercialization,
U.S. Army Medical Research and Development Command
Mr. Datlof is the Chief, Business Development and Commercialization in the Office of Medical Technology Transfer at the U.S. Army Medical Research and Materiel Command. He has commercialized biomedical and IT technologies in the university, nonprofit, for-profit, and government sectors. He owns...
Len Yaffe, MD,
Stoc*Doc Partners
Len Yaffe was the first MD to transition to Wall Street as an analyst many decades ago. He worked primarily at Montgomery Securities in San Francisco, and was recognized as a top analyst in pharmaceuticals, medical devices and drug distribution. He was early in recognizing the impact of intraocular ...
Joe Smyser, Chief Executive Officer,
PGP (The Public Good Projects)
Dr. Joe Smyser is the CEO of The Public Good Projects (PGP), a nonprofit organization that designs and implements large-scale behavior change programs for the public good. PGP selects its work based on three criteria: will it advance public health, will it create change at a large scale, and will...
Dorit Rubinstein Reiss, Professor of Law,
UC Law SF
Dorit Rubinstein Reiss is a professor of law at UC Law San Francisco who specializes in vaccines law and policy, including exemption laws and tort liability related to non-vaccination. She published in law reviews, peer reviewed journals and blogs on legal and policy issues related to...
Mark Navin, Professor and Chair,
Oakland University
Mark C. Navin, PhD, HEC-C, is Professor and Chair of Philosophy at Oakland University, Lecturer in the Department of Foundational Medical Studies at Oakland University William Beaumont School of Medicine, and Clinical Ethicist at Corewell Health. His research focuses on clinical ethics and ethics...
Katie Attwell, Associate Professor,
University of Western Australia
Associate Professor Katie Attwell is a political science and public policy scholar at the University of Western Australia, and a global expert in vaccine hesitancy and vaccination policies for childhood and COVID-19 vaccines. Katie has engaged in community, policy, and behavioural research in...
